Countries Request a quote
CJC-1295 + Ipamorelin Blend — Alphagenics vial
Growth Hormone

CJC-1295 + Ipamorelin Blend

CJC-1295 without DAC / Ipamorelin · Modified GRF (1-29) + Ipamorelin

Combination of a GHRH analog (without DAC) + selective GH secretagogue (GHS-R1a)

Components2
Total5mg / 5mg
Available presentations
Certificate of analysis (COA)
5mg / 5mg
Request a quote View evidence Reconstitution calculator Physician login

About CJC-1295 + Ipamorelin Blend

This presentation combines two peptides that act on complementary pathways of growth hormone release.

CJC-1295 without DAC, also called modified GRF (1-29), is the tetrasubstituted form of GHRH (1-29): D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27. It lacks the DAC group that, in the original CJC-1295, lets it bind to albumin and extends its presence in plasma. It acts on the GHRH receptor of the pituitary. Ipamorelin is a pentapeptide agonist of the ghrelin receptor (GHS-R1a), described as the first selective GH secretagogue. There are no published studies of this blend; the evidence comes from each component and from studies combining GHRH with GH-releasing peptides.

Components per vial

Reference amounts of the formulation. The physicochemical data correspond to each individual peptide.

CJC-1295 (without DAC)

5 mg
YaDAIFTQSYRKVLAQLSARKLLQDILSRNH2 (a = D-Ala)
Molecular formula
C152H252N44O42
Molecular weight
3368.0 g/mol
Length
29 amino acids

Ipamorelin

5 mg
AibHisD2NalDPheLysNH2
Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
PubChem CID
9831659
Length
5 amino acids

Five findings from studies

Summary of results reported in the scientific literature. Each finding describes what was observed in the cited study, in its specific population and conditions; it does not constitute a therapeutic indication.

  1. Preclinical

    In its original characterization in rats, CJC-1295 was described as a tetrasubstituted form of hGRF (1-29); the DAC version, which binds to albumin, remained in plasma for more than 72 h. The CJC-1295 without DAC in this blend keeps the tetrasubstituted sequence without that group.

    Jetté L et al. Endocrinology. 2005;146:3052-3058 · PMID 15817669
  2. Clinical study

    In 10 healthy older men, 14 days of GHRH (1-29), the sequence CJC-1295 is derived from, given subcutaneously twice daily at the high dose, raised 24-hour GH and IGF-1 to values not significantly different from those of young men.

    Corpas E et al. J Clin Endocrinol Metab. 1992;75:530-535 · PMID 1379256
  3. Preclinical

    In rat pituitary cells, in rats and in pigs, ipamorelin has shown GH release with potency and efficacy comparable to GHRP-6. In pigs, it did not significantly raise ACTH or cortisol relative to GHRH, even at doses more than 200 times the ED50 for GH.

    Raun K et al. Eur J Endocrinol. 1998;139:552-561 · PMID 9849822
  4. Clinical study

    In healthy volunteers, ipamorelin has shown dose-proportional pharmacokinetics, with a terminal half-life of about 2 hours and a single episode of GH release per administration.

    Gobburu JV et al. Pharm Res. 1999;16:1412-1416 · PMID 10496658
  5. Clinical study

    In 18 healthy men, combining GHRH with submaximal doses of a GH-releasing peptide (GHRP-6, which acts on the same receptor as ipamorelin) has shown synergistic GH release.

    Bowers CY et al. J Clin Endocrinol Metab. 1990;70:975-982 · PMID 2108187

More in Growth Hormone

SermorelinIpamorelinTesamorelinGHRP-2